Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1978 ARTÍCULOS , VIENDO DEL 31 AL 45

Naturally Inspired Pyrimidines Analogues for Alzheimer's Disease

Singh S, Dhanawat M, Gupta S, Kumar D, Kakkar S, Nair A, Verma I, Sharma P.

Curr Neuropharmacol. 2021;19(2):136-151. doi: 10.2174/1570159X18666201111110136.

Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential

Javaid N, Shah MA, Rasul A, Chauhdary Z, Saleem U, Khan H, Ahmed N, Uddin MS, Mathew B, Behl T, Blundell R.

Curr Pharm Des. 2021;27(34):3591-3601. doi: 10.2174/1381612826666201112144006.

Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease

Uddin MS, Hasana S, Ahmad J, Hossain MF, Rahman MM, Behl T, Rauf A, Ahmad A, Hafeez A, Perveen A, Ashraf GM.

Curr Pharm Des. 2021;27(3):402-414. doi: 10.2174/1381612826666201118092422.

c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations

Busquets O, Parcerisas A, Verdaguer E, Ettcheto M, Camins A, Beas-Zarate C, Castro-Torres RD, Auladell C.

J Alzheimers Dis. 2021;82(s1):S127-S139. doi: 10.3233/JAD-201053.

Molecular Genetics of Early- and Late-Onset Alzheimer's Disease

Uddin MS, Hasana S, Hossain MF, Islam MS, Behl T, Perveen A, Hafeez A, Ashraf GM.

Curr Gene Ther. 2021;21(1):43-52. doi: 10.2174/1566523220666201123112822.

Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation

Liu Y, Cong L, Han C, Li B, Dai R.

Mini Rev Med Chem. 2021;21(8):969-990. doi: 10.2174/1389557520666201127104539.

Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis

Koychev I, Jansen K, Dette A, Shi L, Holling H.

J Alzheimers Dis. 2021;79(1):177-195. doi: 10.3233/JAD-200900.

Current Quest in Natural Bioactive Compounds for Alzheimer's Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence

Iqubal A, Rahman SO, Ahmed M, Bansal P, Haider MR, Iqubal MK, Najmi AK, Pottoo FH, Haque SE.

Curr Drug Targets. 2021;22(6):685-720. doi: 10.2174/1389450121999201209201004.

The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators

Pan L, Ma Y, Li Y, Wu H, Huang R, Cai Z, Wu X.

Mini Rev Med Chem. 2021;21(11):1288-1302. doi: 10.2174/1389557520999201209211610.

Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial

Moline M, Thein S, Bsharat M, Rabbee N, Kemethofer-Waliczky M, Filippov G, Kubota N, Dhadda S.

J Prev Alzheimers Dis. 2021;8(1):7-18. doi: 10.14283/jpad.2020.69.

Long Chain Omega-3 Fatty Acid Intervention in Ageing Adults at Risk of Dementia Following Repeated Head Trauma. Low-level Support or an Opportunity for an Unanswered Question?

Patch CS, Hill-Yardin EL, Ryan L, Daly E, Pearce AJ.

J Prev Alzheimers Dis. 2021;8(1):29-32. doi: 10.14283/jpad.2020.49.

Rapid drug access and scientific rigour: a delicate balance

The Lancet Neurology.

Lancet Neurol. 2021 Jan;20(1):1. doi: 10.1016/S1474-4422(20)30452-X.

APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches

Serrano-Pozo A, Das S, Hyman BT.

Lancet Neurol. 2021 Jan;20(1):68-80. doi: 10.1016/S1474-4422(20)30412-9.

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1) -receptor partial agonist for the treatment of dementias

Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ.

Br J Clin Pharmacol. 2021 Jul;87(7):2945-2955. doi: 10.1111/bcp.14710. Epub 2021 Feb 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias